| Disease | FOLLOWING ORAL ADMINISTRATION OF ECG, ECG PLASMA LEVELS REVEALED CURVES CHARACTERIZED BY PEAKS AT 0.065, 0.063 AND 0.085 H CORRESPONDING TO DASAGES OF 12.5, 25.0 AND 50.0 MG/K AT MEAN CONCENTRATIONS OF 49.62, 212.89 AND PHARMACOKINETICS IN TERMS
OF CMAX AND AUCO(0-INF). THE ABSOLUTE BIOAVAILABILITY VALUES (F) WERE 1.02, 1.47 AND 3.30% AT DOSES OF 12.5, 25.0 AND 50.0 MG/KG, RESPECTIVELY. FOLLOWING ORAL ADMINISTRATION OF ECG, URINARY LEVELS OF ECG WERE LOWER THAN THE QUANTITATION LIMIT.
MOREOVER, CUMULATIVE EXCRETION OF THE METABOLITES, GAMMA-(2,4-DIHYDROXYPHENYL)-GAMMA-VALEROLACTONE AND GAMMA-(3-METHOXY-4-HYDROXYPHENYL)-GAMMA VALEROLACTONE, WAS 2.45 AND 0.23% OF DOSE, RESPECTIVELY, UP TO 30 H AFTER DOSING. |